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Abstract 
Carcinogenesis  is  believed  to  be  a  multi-step  process,  progressing  sequentially  from 
normal to hyperplastic, to in situ, and to invasive stages. A number of studies, however, 
have detected malignancy-associated alterations in normal or hyperplastic tissues. As the 
molecular profile and clinical features of these tissues have not been defined, the authors 
invited several well-recognized pathologist, oncologists, biologist, surgeons, and molec-
ular biologist to offer their opinion on: (1) whether these tissues belong to a previously 
unrevealed malignant entity or focal alterations with no significant consequence? (2) 
whether these alterations are linked to early onset of cancer or cancer of unknown pri-
mary site, and (3) how to further define these lesions? 
Key words: Malignant transformation; Tumor invasion; Sick lobe; Tumor microenvironment; Tu-
mor capsule 
Introduction 
It is a commonly held belief that carcinogenesis 
is a multi-step process, progressing sequentially from 
normal  to  hyperplastic,  to  in  situ,  and  to  invasive 
stages [1-3]. Progression from one stage to another is 
believed  to  result  from  increasing  accumulation  of 
hereditary  mutations  in  major  regulatory  genes  or 
uncorrected and acquired mutations in somatic genes 
[4-6].  It  is  estimated  that  an  average  of  16  years  is 
needed for a cancer-initiating cell to develop into a 
10-mm, clinically detectable tumor, as  the averaged 
volume  doubling  time  in  most  tumors  is  about 
210-days during exponential growth [7-9].  
A  vast  majority  of  the  studies  during  the  past 
have  consistently  shown  that  a  number  of  genetic, 
biochemical, and morphologic alterations, including a 
loss of heterozygosity (LOH), aberrant expression of 
p53, c-erbB2, CA-125, disruptions of the tumor cap-
sule,  and  stromal  or  vascular  invasion  of  epithelial 
cells,  are  exclusively  or  almost  exclusively  seen  in 
malignant  lesions  [10-14]. Consequently,  these  have 
been considered as malignancy-associated alterations 
(MAA) or malignant tumor signatures [10-14].  
However,  a  number  of  studies  have  reported 
that: (1). The same pattern of LOH at several chro-
mosome loci was detected in both breast cancer tis-
sues and in adjacent morphologically normal lobules 
[15],  (2).  Some  morphologically  normal  ductal  in-
traepithelial  neoplasia  (flat  type)  shared  the  same 
LOH and monoclonality identified in adjacent in situ 
and invasive ductal carcinoma [16], (3). Some healthy 
men between 19-29 years old showed a spectrum of 
proliferative abnormalities, including atypical hyper-
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plasia, prostatic intraepithelial neoplasia, or invasive 
cancer  [17-19],  and  (4).  Prostate  tissues  of  certain 
healthy  man  or  normal  tissues  adjacent  to  prostate 
cancer  showed  a  DNA  phenotype  identical  to  the 
DNA structure of invasive prostate cancer [20-22].  
More recent studies have further revealed that 
about 15% of human breast and prostate tumors har-
bor variable numbers of morphologically normal or 
hyperplastic  ductal  and  acinar  structures  with  ma-
lignancy-associated  alterations,  including  aberrant 
expression of p53 and c-erbB2, focal disruptions of the 
tumor capsules, and morphological signs of stromal 
or vascular invasion [23-33]. These structures are dis-
tributed as clusters or lobules with a distinct bound-
ary  to  adjacent  counterparts.  Microdissected  cells 
from these clusters or lobules showed a substantially 
elevated frequency of genetic instabilities and expres-
sion of invasion-related genes [24].  
These findings suggest that the linear model of 
tumor progression [1-3] may not apply to all cases, 
and that the morphological features of some tissues 
may  not  fully  reflect  their  genetic  and  biochemical 
profiles. However, as only a few such cases have been 
reported, it is not clear whether these tissues represent 
a  previously  unrevealed  malignant  entity,  or  focal 
changes with no major consequences. In addition, the 
structural relationships of these tissues with their ad-
jacent counterparts have yet to be revealed. Thus, our 
current study intends to expand our previous obser-
vations,  to  assess:  (1)  whether  cells  with  malignan-
cy-associated  changes  could  originate  from  these 
structures, (2) whether these structures are in physical 
continuity  with  distinct  invasive  lesions,  and  (3) 
whether aberrant leukocyte infiltration correlates with 
malignancy-associated alterations within these struc-
tures.  
Materials and Methods  
Five cases harbored large normal human breast 
ductal  or  acinar  clusters  or  lobules  with  malignan-
cy-associated alterations were selected from our pre-
vious studies [23-33], in which all tissue samples were 
retrieved from files of the Armed Forces Institute of 
Pathology.  Consecutive  sections  at  7-um  thickness 
were  prepared  and  placed  sequentially  on  positive 
charged slides. For each set of 10 sections, the first 3-4 
sections  were  used  for  H&E  staining  and  immuno-
histochemistry. The remaining sections were used for 
different molecular assays.  
To  identify  malignancy-associated  alterations, 
two-technical approaches were used. First, the phys-
ical  integrity  of  the  capsule  surrounding  epithelial 
structures was examined with tumor capsule specific 
markers, smooth muscle actin (SMA; clone:1A4; Sig-
ma, St. Louis, MO, USA) and/or collagen IV (clone: 
CIV22, Dako, Carpinteria, CA, USA). Immunostained 
sections were examined under high magnification to 
identify the absence or focal disruptions of the tumor 
capsule (defined as the absence of myoepithelial cells 
and/or the basement membrane that results in a gap 
greater  than  the  combined  size  of  at  least 
3-myoepithelial  cells).  Second,  sections  were  double 
imunostained  for  SMA  and  p53  (clone:  D07,  Dako, 
Carpinteria,  CA,  USA)  or  c-erbB2  (clone:10A7;  No-
vocastra, Newcastle, UK). To differentiate ductal from 
acinar cells and to assess the impact of aberrant leu-
kocyte infiltration on physical integrity of the myoep-
ithelial  cell  layers  and  adhesion  molecules,  sections 
were  double  immunostained  for  E-cadherin  (clone: 
36B5; Lab Vision, Fremont, CA,USA) and leukocyte 
common  antigen  (LCA,  clone:2B11+  PD7/26,  USA). 
To identify isolated epithelial cells within leukocyte 
aggregates, sections were double immunostained for 
LCA  (which  reacts  with  all  hematopoietic  cells,  in-
cluding lymphocytes) and cytokeratin (CK) AE1/AE3 
(clone; AE1/AE3, Dako, Carpinteria, CA,USA) (which 
react with all epithelium derived cells). The biological 
presentation  and  tissue  microenvironment  were  as-
sessed with a panel of biomarkers, including ER, PR, 
Ki-67, CK5, CK19, CD31, D2-40, and others. 
Immunostaining  was  carried  out  following 
manufactures’  instruction.  The  secondary  antibody, 
ABC  detection,  and  DAB  chromogen  kits  were  ob-
tained  from  Vector  Laboratories  (Burlingame,  CA, 
USA). The AP red-chromogen kit was purchased from 
Zymad Laboratories (South San Francisco, CA, USA). 
To assess the specificity of the immunostaining, nega-
tive controls included (1) the substitution of the pri-
mary antibody with the same isotype or pre-immune 
serum  of  the  antibody,  and  (2)  the  omission  of  the 
secondary antibody. The immunostaining procedure 
was repeated at least twice using the same protocol 
and the same conditions. A given cell was considered 
immunoreactive  if  distinct  immunoreactivity  was 
consistently seen in its cytoplasm, membrane, or nu-
cleus, while all negative controls lacked distinct im-
munostaining.  
Results  
Each  case  harbored  variable  numbers  of  mor-
phologically normal- or hyperplastic-appearing duc-
tal or acinar cells, which were distributed as clusters 
or lobules with a distinct boundary to adjacent coun-
terparts. The size of these clusters or lobules varied 
from  about  one  hundred  to  several  thousand 
cells/per profile, and extended from about 50 to over 
400 sections (about 350 - 3,000-um). Compared to ad-
jacent  morphologically  clear-cut  normal  or  hyper- Journal of Cancer 2011, 2 
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plastic counterparts, these ductal and acinar clusters 
or lobules have the following unique profiles:  
1.  They  are  indistinguishable  from  adjacent 
counterparts  in  H  &  E  stained  sections  under  low 
magnification,  but  under  high  magnification,  they 
often show a high nuclear-cytoplasm ratio and sub-
stantially enlarged nucleoli.  
2. In sections immunostained for tumor capsules, 
the myoepithelial cell layer and basement membrane 
of these structures are generally discontinuous or fo-
cally disrupted, or even totally absent. 
3.  They  were  exclusively  associated  with  large 
leukocyte  aggregates,  which  completely  or  partially 
surrounded  these  structures.  Some  leukocytes  were 
directly  attached  to  the  myoepithelial  cell  layers. 
Within leukocyte aggregates, a significant number of 
isolated epithelial cells was seen.  
4. Neither distinct in situ carcinoma nor enlarged 
tumor nests (with over 50-cells/nest) were seen.  
5.  In  the  superficial  cuts, p53-positive  cell  was 
not  detected.  The  number  of  p53-positive  cells  in-
creased linearly in the deeper cuts, and eventually, the 
entire lobule was replaced by p53-positive cells.  
6. These p53-positive cells lacked E-cadherin ex-
pression with morphological features of lobular cells. 
These p53-positive cells also lacked the surrounding 
myoepithelial cell layer and the basement membrane, 
a typical feature of invasive cancers.  
7.  These  p53-positive  cells  were  eventually 
blended with morphologically distinct invasive can-
cer cells.  
8.  Leukocyte  aggregates  were  exclusively  or 
preferentially located at the junctions between these 
normal appearing structures and invasive lesion, and 
seemed to “flow” or “migrate” to different locations, 
correlating with the emergence of p53-positive cells.  
The above features are depicted in the following 
two  sets  of  consecutive  sections.  The  first  set  eluci-
dates  malignancy-associated  alterations  in  lobules 
distant  from  invasive  lesion.  The  second  set  shows 
similar alterations in a normal-appearing lobule im-
mediately adjacent to the invasive component. Each 
number  at  the  figure  sets  represents  the  sequential 
number of the sections. 
In summary, the above findings from consecu-
tive sections indicate that:  
1. These clusters or lobules were not associated 
with morphologically distinct in situ or large tumor 
nests.  
2.  Cells  with  malignancy-associated  alterations 
(including strong p53-positivity, the absence of my-
oepithelial cell layers and the basement membrane, a 
high  nuclear-cytoplasm  ratio  and  substantially  en-
larged  nucleoli,  significantly  elevated  cell  prolifera-
tion, morphological resemblance and physical conti-
nuity with invasive lesions, and disassociation from 
main  structures)  could  originate  from  morphologi-
cally normal structures.  
3.  The  number  of  cells  with  malignan-
cy-associated alterations linearly increased in consec-
utive  sections,  and  these  cells  were  eventually 
blended  with  morphologically  distinct  invasive  le-
sions.  
4. Leukocyte aggregates were exclusively located 
at the junctions between these structures and invasive 
lesion, and seemed to “flow” or “migrate” to different 
locations, correlating with emergence of p53-positive 
cells. Together, these findings suggest that malignant 
transformation and stromal invasion could originate 
or emerge from morphologically normal structures.  
Discussion  
Based  on  these  and  previous  findings,  these 
morphologically normal- or hyperplastic-clusters and 
lobules  seem  to  represent  a  previously  unrevealed 
malignant entity that has acquired significant genetic 
abnormalities and could directly progress to invasive 
or metastatic breast lesions. This speculation is con-
sistent with the “sick lobe” theory of breast carcino-
genesis proposed by Tot at al [34, 35], which suggests 
that “The sick lobe carries some kind of genetic insta-
bility already from its initialization during the early 
embryonic  life  and  is  more  sensitive  to  noxious  in-
fluences than the other lobes within the same breast”.  
The exact cause for the formation of these lobules 
is unknown, but could potentially result from diag-
nostic or therapeutic radiation exposure at the  very 
early age [36,37], which may have resulted in signifi-
cant genetic damages on a subset of stem cells within 
these lobules, especially those for myoepithelial cells. 
Myoepithelial cells are also very sensitive to certain 
chemicals.  For  example,  exposure  to  lambdacarra-
geenan can specifically result in filament disassembly 
and loss of myoepithelial cells, whereas exposure to 
oxytocin  could  substantially  enhance  myoepithelial 
cell differentiation and proliferation in mouse breasts 
[38,39]. Damages to myoepithelial stem cells can di-
rect  impair  the  normal  replenishment  process,  re-
sulting in an aged or inactive myoepithelial cell pop-
ulation.  As  the  myoepithelial  cell  layer  is  the  sole 
source of several tumor suppressors, damages to this 
cell layer could lead to the loss of its paracrine inhib-
itory functions on tumor cell proliferation [40-42].  
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Figure 1. MMA in lobule distant from invasive lesion.  Journal of Cancer 2011, 2 
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Figure 2. MAA in lobule adjacent to invasive lesion.  Journal of Cancer 2011, 2 
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The mechanism(s) for progression of these nor-
mal-  or  hyperplastic-appearing  tissues  is  also  un-
known, but it appears to  be triggered by  leukocyte 
infiltration for the following reasons: (1). Pregnancy 
associated  and  inflammatory  breast  cancers,  which 
have extensive leukocyte infiltration, have the most 
aggressive clinical course and worst prognosis among 
breast  malignancies  [43,44],  (2).Increased  leukocyte 
infiltration correlated with substantially elevated tu-
mor cell proliferation in prostate tumors [45], (3). In-
creased  leukocyte  infiltration  correlated  with  pro-
gression  of  oral  epithelium  from  hyperkeratosis  to 
dysplasia, and to carcinoma [46], and (4). Pre-invasive 
prostate  tumors  with  chronic  inflammation  had  a 
significantly  higher  rate  of  subsequent  invasive  tu-
mors  than  morphologically  similar  lesions  without 
chronic inflammation [47].  
Our recent in vitro study has revealed that pro-
tease-degraded collagen I fragments could function as 
a specific mediator to attract macrophage infiltration 
[48].  Thus,  the  formation  of  leukocyte  aggregates 
within these clusters or lobules is likely to result from 
increased degradation of the myoepithelial cells and 
the  basement  membrane.  Our  previous  studies  in 
multiple types of human tumors, including those in 
breast, prostate, cervix, and lung, have revealed that 
leukocytes could facilitate tumor cell invasion or me-
tastasis  through  3-correlated  pathways  [32,49]:  (1). 
The physical movement of leukocytes into the epithe-
lial cells disrupts the inter-cellular junctions and cell 
surface  adhesion  molecules,  causing  the  disassocia-
tion of tumor cells from the tumor core, (2). Leuko-
cytes  are  conjoined  with  some  of  these  tumor  cells 
through  plasma  membrane  fusion,  creating  tumor 
cell–leukocyte  chimeras  (TLCs),  and  (3).  The  leuko-
cytes of TLCs impart migratory capacity to the asso-
ciated tumor cell partners, physically dragging them 
to different tissue sites.  
Thus, the entire luminal cell population within 
these  clusters  or  lobules  could  directly  invade  the 
stroma when its entire surrounding myoepithelial cell 
layer become degenerated and disrupted. Although 
these cells might not possess all the properties of in-
vasive  cancer  cells,  the  changed  microenvironment 
may act as a second “hit” to trigger a cascade reaction 
of  malignant  transformation  that  rapidly  alters  the 
genetic and biochemical  profiles of these cells. This 
speculation is supported by the fact that major sin-
gle-gene defects, such as a mutation in the BRCA1 or 
BRCA2, could cause significantly higher cancer inci-
dence and early cancer onset in their inheritance pat-
terns [50]. This speculation is further supported by a 
recent study, which has shown that interstitial flow 
emanated from tumors into their microenvironment 
could  promotes  tumor  cell  invasion  by  influencing 
cell  behavior  and  modulating  cell-cell  interactions 
[51,52].  
Due to these unique presentations, these “sick” 
lobules or cell cluster may represent the “seeds” or 
precursors for cancer of unknown primary site, which 
is one of the 10 most frequent cancers worldwide and 
ranks as the 4th most common cause of cancer-related 
death [53-55]. The development of early, uncommon, 
systemic  metastasis,  and  resistance  to  therapy  are 
hallmarks of this clinical entity or condition/outcome. 
In addition, these “sick” lobules or tissues could also 
be  potentially  associated  with  childhood  cancer 
[36,37], in which diagnostic or therapeutic radiation 
exposure function as a cancer “initiator” or “promot-
er”.  
However,  a  conclusive  classification  of  these 
normal  appearing  structures  could  not  be  made  at 
present for the following reasons: (1) aberrant expres-
sion of p53 or e-cebB2 is not a conclusive sign of tu-
mor malignancy, (2) a genome-wide comparison with 
distinct malignant lesions has not been made, (3) the 
large  lobule  structures  are  seen  mainly  in  pregnan-
cy-associated cancer, which may not be highly repre-
sentative  for  the  general  population,  (4)  no  clinical 
follow-up data are available for these cases, and (5) 
we need to test more samples to demonstrate statisti-
cal significance. On the other hand, as it is estimated 
that an average of 16 years (30-doubling times) are 
needed for a cancer-initiating cell to develop into a 
10-mm,  clinically  detectable  tumor  [7-9],  it  is  also 
possible that these malignancy-associated alterations 
in these normal or hyperplastic appearing structures 
may be focal and transient with no significant conse-
quences.  
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